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We have examined the effect of Rev on the regulation of the expression of RRE containing 
mRNAs when they were synthesised in the nucleus or directly in the cytoplasm. In the 
nuclear expression system, Rev enhanced env mRNA transport by about 1.6-fold, while 
translation of this mRNA was increased more than a 100fold. These findings indicate that 
the target of Rev activity is located mainly at the translational level. Synthesis of Env using a 
recombinant vaccinia virus system, that synthesised env mRNA directly in the cytoplasm, is 
also enhanced by Rev. Finally, RRE functioning was examined using a luciferase mRNA 
bearing this element. Rev stimulated the synthesis of Luciferase both when the luc mRNA 
was made in the nucleus or in cytoplasm. Our results indicate that the effect of Rev on env 
mRNA transport is low as compared with the enhancement of translation of this mRNA. 
 
1. Introduction  
  
Protein synthesis in human immunodeficiency virus type 1 (HIV-1) infected cells is 
regulated in a temporally manner by several factors including Rev protein (reviewed in [1]). 
Late viral genes express unspliced or single spliced mRNAs that require Rev protein to render 
Gag, Pol, Env, Vif, Vpr and Vpu. Several hypotheses have attempted to explain how Rev 
promotes the transport and translation of viral mRNAs containing the Rev responsive 
element (RRE). Most of these have emerged from studies focussing on the role played by 
Rev in aiding the transport of viral messengers from the nucleus to the cytoplasm, and/or on 
the increase in mRNA stability [2,3]. Rev interacts with the RRE that maps at conserved 
region of the HIV env gene [4,5]. A repressive sequence that overlaps the RRE domain is 
responsible for the low expression of viral structural genes by nuclear retention of unspliced 
or single spliced viral mRNAs [6]. The binding of Rev protein to the RRE motif induces efficient 
cytoplasmic export and translation of RRE-containing mRNAs [7]. Upon interaction with 
multiple cell cofactors, Rev promotes the translocation of Rev-RRE ribonucleoprotein 
particles across the nuclear membrane. The NES domain of Rev interacts with cellular CRM-
1 protein, a member of the nucleoporin family [8]. This interaction has been suggested to 
facilitate the nuclear egress of HIV-1 transcripts bearing the RRE sequence [9]. Other 
sequences that differ from the RRE domain, the INS elements, may be responsible for the 
low expression of gag/pol genes, though the interaction of Rev with the RRE counteracts the 
negative effects of these inhibitory sequences [10].  
As well as regulating the splicing and transport of RRE-containing mRNAs, Rev 
enhances their translation in the cytoplasm. Thus, Rev was able to stimulate protein 
synthesis in transfected 729 B cells by 27-fold, while only a 3-fold increase was observed in 
cytoplasmic intron-containing HIV RNA levels [11]. HeLa cells, constitutively expressing Tat, 
transfected with a gag expression plasmid, synthesised significant levels of gag mRNAs that 
localised in the cytoplasm, but their translation was low in the absence of Rev. Notably, Rev 
led to a 4 to 16-fold increase in cytoplasmic mRNA levels in HeLa cells and to an 800-fold rise 
in Gag protein synthesis [12]. In vitro translation of these mRNAs revealed their functionality 
even in the absence of Rev. HeLa cells transfected with a plasmidcontaining defective virus, 
in which the pol, vif and vpr genes are deleted, exhibited reduced viral mRNA levels in the 
cytoplasm in the absence of Rev. Moreover, the gag and vpu/env mRNAs present in the 
cytoplasm were not translated when the functional rev gene was lacking [13]. Cotransfection 
of a rev defective proviral mutant and a rev expression plasmid showed a Rev-dependent 
increase in the amount of gag/pol mRNA associated with polysomes. Similarly, the amount 
of vpu/env mRNA in polysomes was also increased [12]. Regulation of HIV-1 gene expression 
by Rev protein has been related to the targeting of RRE-containing RNA to components of 
the cellular translation complex, such as eIF5A in Xenopus oocytes [14] and lymphocytes 
[15]. Transfection of HeLa cells with a Rev-defective HIV expression plasmid gave rise to 
significant gag and env mRNA levels in the cytoplasm [16]. Under these conditions, efficient 
viral protein production was strictly dependent on the presence of Rev. Moreover, 
 
association of gag mRNA with cytoskeletal proteins in the perinuclear clusters where viral 
protein synthesis  
begins was only observed in the presence of Rev [16]. Here, we report that mRNA translation 
is enhanced by Rev, even when the env messenger is transcribed in the cytoplasm, indicating 
that nuclear transport is not necessary for the Rev induced stimulation.  
  
2. Materials and methods  
  
2.1. Constructs and antibodies  
To generate the expression vector pTM1-rev, the coding region of HXB3 Rev [17] was 
amplified by polymerase chain reaction from pCMVinsrev plasmid, kindly provided by B.R. 
Cullen (Duke University. Durham, NC. USA). The PCR amplified cDNA fragment was inserted 
into the Nco I and BamH I sites of pTM1.  
The primers used were: 5’ (GGGGCCCATGGCAGGAAGAAGCGGA), and 3’ 
(GGGCCCAGATCTCTATTCTTTAGCTCC). The pCDNA-rev construct was  
obtained by inserting the Kpn I/Xho I rev fragment from pTM1-rev into the pCDNA plasmid. 
The pKS-env vector was constructed from pHXB2-env plasmid [18], obtained from the AIDS 
Research and Reference Reagent Program, Division of AIDS, NIAID, NIH. The EcoR I/Bcl I 
fragment obtained by enzyme digestion was inserted into the pBluescript KS. Similarly, EcoR 
I/Bcl I fragment encoding env gene was inserted into pTM1 plasmid. The pCDNA-env 
plasmid was constructed by cloning the EcoR I/Xho I fragment of pTM1-env into the pCDNA 
plasmid. pKSluc contains a BamH I fragment with intronless sequence of the firefly 
luciferase gene [19]. Downstream from the reporter gene, a PCR fragment containing 351 
nucleotides of RRE region [20] (7066-7416 fragment of isolate BH10) was inserted in the pKS-
luc plasmid to generate pKS-RREluc. The primers used were 5’  
(GGGGGGGATATCTAGCACCCAAGG) and 3’  
(GGGGGGAAGCTTTAGCATTCCAAGGCA). The PCR fragment was digested  
with EcoR V and Hind III and then inserted into pKS-luc plasmid, which previously was 
digested with Sma I and Hind III enzymes. pCDNA-luc and pCDNA-RREluc were directly 
obtained from pKSluc and pKS-RREluc by restriction digestion, using Apa I/Not I and BamH 
I/Xho I, and insertion of the luc and RREluc fragments, respectively, into the pCDNA plasmid. 
The monoclonal antibody to HIV-1 Rev, generously provided by Dr J. Karn (Cambridge, UK.), 
and the rabbit serum antiHIV-1/gp120, donated by Dr S. Ranjbar (Herts, UK.), were obtained 
from the NIBSC Centralised Facility for AIDS Reagents (supported by the EU Program EVA 
and the UK Medical Research Council).  
 
2.2. Transfection and luciferase assays  
The env and rev genes were efficiently expressed, under the control of the 
bacteriophage T7 promoter, in human HeLa and simian COS cells infected with T7-
recombinant vaccinia virus and transfected with the pKS-env and pTM1-rev plasmids, 
respectively, using lipofectin reagent (Gibco-BRL) [21]. Both genes were also expressed from 
pCDNA-env and pCDNA-rev plasmids transfected in human 293 cells using a calcium 
phosphate protocol [22]. Luciferase constructs of pCDNA-luc and pKS-luc were also 
transfected using calcium phosphate or lipofectin reagent, respectively. Luciferase activity 
was measured as described  
[23].  
2.3. Western blotting  
Entire cell lysates were fractionated on sodium dodecyl sulphatepolyacrylamide gel 
electrophoresis (SDS-PAGE) gels with 10% (anti-gp120) or 15% (anti-Rev blots) 
polyacrylamide, transferred to nitrocellulose membranes by wet immunotransfer, and 
processed for Western blotting. The blots were probed with an antibody to gp120 or Rev. 
Goat-peroxidase-conjugated anti-rabbit or antimouse antibodies (Pierce) and the ECL kit 
(Amersham) were used to detect bound antibodies. Chemiluminescence was detected by 
exposure to Agfa X-ray film.  
2.4. Cell fractionation in nucleus and cytoplasm  
Forty eight hours after transfection, the 293T cell monolayer was washed with PBS 
and the cells then harvested in buffer containing 10 mM Tris-HCl [pH  
8.5], 150 mM NaCl, 1.5 mM MgCl2, 1 mM dithiothreitol, 1 mg/ml yeast tRNA, 2 mM RNAse 
inhibitor and 0.5% IGEPAL CA-630. After mixing, the cell extract was incubated at 4 ºC for 5 
min and then centrifuged at 3,000 rpm and 4 ºC for 2 min. The supernatant and pellet 
fractions were used to analyse protein and RNA contents in the cytoplasm and nucleus of 
transfected cells.  
2.5. Reverse transcription and PCRs  
Total RNA was purified from the cytoplasmic fraction of transfected cells using the 
TRIzol reagent (Invitrogen), DNAse I treated and phenol-chloroform extracted. env mRNA 
was amplified using the RT-PCR one step protocol in a total volume of 50 μl. The reaction 
mixture containing: 0.5 μg RNA, 10 μl reaction buffer  
(Promega), 10 mM of each dNTP, 50 pmoles of each primer (5’  
GGGGGGGATATCTAGCACCCACCAAGG and 3’  
GGGGGGAAGCTTTAGCATTCCAAGGCA), 25mM MgSO4, and 5 units of AMV and Tfl 
polymerases was incubated at 48 ºC for 45 min for the reverse transcription reaction. 
Amplification reactions were performed for 30 cycles at 94 ºC for 30 sec, 60 ºC for 1 min, 
and 68 ºC for 2 min, with a final extension at 68 ºC for 7 min. Real time PCR reaction was 
 
carried out using the Light Cycler-FastStart DNA Master SYBR Green I kit (Roche) according 
to the manufacturer's instructions. Briefly, the cDNA obtained by reverse transcription was 
amplified in 10 μl of reaction volume, containing 1.2 μl reaction mix, 3.5 mM MgCl2 and 10 
μM of each primer. The amplification reaction was performed at 95 ºC for 10 min, followed 
by 45 cycles at 95 ºC for 5 sec, 59 ºC for 5 sec and 72 ºC for 10 sec. To determine mRNA 
concentration, a control RT-PCR quantitative reaction was performed using standard cell 
oligonucleotides in which glyceraldehyde 3-phosphate dehydrogenase was amplified.  
2.6. Immunoprecipitation  
Cells were metabolically labelled with a [35S]methionine-cysteine mixture 
(Amersham) (1.2 mCi/ml) for 1 hour. The cells were then washed with ice-cold  
PBS, harvested in immunoprecipitation buffer (250 mM NaCl, 5 mM EDTA, 25 mM Tris-HCl 
(pH 7.5) and 1% NP-40) and incubated at 4 ºC for 30 min. The cell lysate was centrifuged at 
10,000 x g for 15 min to remove particulate debris. The supernatant was incubated for 1 h 
at 4 ºC with protein A-Sepharoseimmunoglobulin G complexes and then centrifuged at 
10,000 xg for 20 sec. The precleared supernatant was incubated overnight with specific 
antibody. Immune complexes were precipitated with protein A-Sepharose for 1 h at 4 ºC. 
After three washes with immunoprecipitation buffer, analysis of precipitate complexes was 
carried out by SDS-PAGE and autoradiography.  
  
3. Results  
3.1. Stimulation of Env synthesis by Rev using a nuclear expression system.  
Initially, our aim was to assess whether Rev could stimulate the expression of env 
obtained from an HXB2 HIV-1. To this end, the cDNA encoding Env, together with its 5’ leader 
sequence, was introduced in a pCDNA plasmid, an expression vector containing the CMV 
promoter. The Rev encoding sequence of HIV-1 was also introduced in a pCDNA plasmid. 
Both recombinant plasmids were then used to cotransfect human 293 cells. 
Immunofluorescence analysis with nonpermeabilized cells revealed the location of HIV-1 
glycoproteins at the cell surface only when Rev was present (results not shown). Our next 
goal was to estimate the amount of cytoplasmic env mRNA occurring in the absence or 
presence of Rev. This was achieved by lysing and separating cotransfected cells 48 h.p.t. into 
nuclear and cytoplasmic fractions. The amount of HIV-1 Env in the cytoplasmic fraction was 
then determined by western blotting. Figure 1A shows that gp160 is only observed when Rev 
is expressed. This demonstrates that in this system and under the conditions used there is a 
profound stimulation of Env synthesis only in the presence of Rev. The extent of Rev 
stimulation of Env synthesis could not be determined by densitometric scan analysis since 
no gp160 was detected in the absence of Rev. However, bearing in mind the sensitivity of 
this assay, this quantification suggested that it was several hundred fold. This finding agrees 
well with the enhancement noted using other systems [12]. As a control, luciferase synthesis 
was also determined (Figure 1B). Almost no differences were found in cytoplasmic luciferase 
 
in the absence or presence of Rev. This finding indicates that Rev does not unspecifically 
enhance the synthesis of any protein. Besides, the nuclear fraction showed no luciferase 
activity (data not shown), indicating no contamination from the cytoplasm. This can also be 
inferred upon analysis of the RNAs present in both fractions (Figure 1C). To estimate the 
amount of env mRNA, RT-PCR analysis of total purified RNA, after DNAse I digestion, was 
carried out. This PCR amplification yielded a RRE fragment from env mRNA (Figure 1D). The 
env amplified product was quantified by real-time PCR. Rev stimulated the amount of env 
mRNA present in the cytoplasm 1.6-fold (Figure 1E). Our results indicate that although Rev 
enhances the amount of cytoplasmic env mRNA, most of the enhanced Env synthesis 
observed in this system occurs directly at the translational  
level.   
3.2. Stimulation of Env synthesis by Rev using a cytoplasmic expression 
system  
  Once we had established that nuclear synthesised env mRNA responded to Rev, a 
cytoplasmic expression system was used to explore Env synthesis in the presence or absence 
of Rev. To this end, the vaccinia recombinant virus (VT7) and a T7 promoter driven plasmid 
(pTM1) were used to simultaneously express Rev and Env proteins. Cotransfection of both 
plasmids was performed in HeLa or COS cells. Initially, different pTM1-rev concentrations 
were assayed keeping constant the amount of pKS-env. Figure 2 (Panel A) shows the western 
blotting using antibodies against Env. Clearly, the accumulation of Env is dependent on the 
amount of pTM1-rev employed as estimated by western blotting. This stimulation was more 
apparent in HeLa cells than in COS cells. Higher concentrations of this plasmids interfered 
with the transfection assay (Data not shown). In order to test the actual synthesis of Env, 
transfected cells were radioactively labelled and immunoprecipitation was carried out.  An 
enhancement of Env synthesis of about 6-fold was noted in HeLa cells in the presence of 
Rev, while no such enhancement was observed in COS cells (Figure 2B). This suggests that 
Rev is able to stimulate the translation of the env mRNA present in the cytoplasm of human 
cells, but not in those of simian origin. Alternatively, it could be that Rev does not stimulate 
Env synthesis in COS cells, because mRNA translation is sufficiently efficient in the absence 
of Rev. As a control, Rev synthesis was determined when the pTM1-rev was employed in 
both cell types; a higher expression level was observed using COS cells (Figure 2C). These 
findings are in accordance with previous results illustrating that gene expression using the 
VT7 system is more efficient in COS than in HeLa cells [24].  
The aminoglycoside antibiotic neomycin B blocks the stimulation of RRE- containing 
mRNAs by Rev [25]. The presence of this compound inhibited the stimulation of Env 
synthesis by Rev in the cytoplasmic system using recombinant VT7 in HeLa cells (Figure 2D). 
The antibiotic failed to block total protein synthesis, indicating that the inhibition of Env 
synthesis stimulation is selective. We can therefore conclude that the enhancement of Env 
synthesis by Rev in the HeLa cell cytoplasmic system is mediated by the Rev/RRE interaction. 
These findings further support the idea that Rev is able to stimulate the translation of an 
mRNA synthesised in the cytoplasm.  
 
3.3. Translation of luciferase mRNA containing RRE  
To compare Rev activation of the translation of RRE-containing mRNAs with that of 
mRNAs lacking this element, the two expression systems described above were employed. 
Two different luciferase encoding mRNAs were tested, one of which bears the RRE element 
(351 bp) [20] as depicted in Figure 3A. The responsiveness of these mRNAs to Rev when they 
are synthesised in the nucleus was analysed by measuring luciferase activity at 48 h.p.t. 
(Figure 3B). Almost no differences in luciferase activity were noted in the absence or 
presence of Rev in conditions of two different rev/luc plasmid proportions when the RRE-
lacking luc mRNA was tested. The two rev/RREluc plasmid proportions analysed gave rise to 
a 2- or 3-fold stimulation of luciferase synthesis. Thus, although the presence of the RRE in 
the luc mRNA confers some stimulation capacity upon Rev, this enhancement seems to be 
far below that related to the more physiological mRNA, env mRNA. Notably, it was also 
possible to observe clear stimulation of luciferase synthesis by Rev when the VT7 system was 
employed (Figure 3C). This stimulation may reach 3-fold. This level of Rev-induced activation 
of RREluc mRNA translation was similar to that observed using the nuclear system. 




4. Discussion  
  
  Gene expression in HIV-infected cells is regulated at both the transcriptional and 
translational level by a number of cellular and viral factors. The regulatory functions of Rev 
are exerted at several posttranscriptional steps, i.e., the modulation of splicing, transport of 
mRNAs from the nucleus to the cytoplasm and enhanced translation of RRE-containing 
mRNAs. Upon transcription and processing, mRNAs interact with several proteins that 
govern their transport through nuclear membrane pores. The interaction of Rev with an 
array of these proteins promotes the exit of viral mRNAs that posses the RRE motif from the 
nucleus. The dependence of this transport on Rev may vary from one cell type to another. 
Thus, in some cells, the cytoplasmic accumulation of RRE-containing viral mRNAs is not much 
affected by the presence or absence of Rev. However, in other cells, the transit of these 
RNAs through the nuclear membrane is largely dependent on Rev function. In the human 
293 cell line used here, Rev moderately enhanced the transport of env mRNA to the 
cytoplasm. This suggests that Rev function is replaced, at least in part, by a cell protein or 
that Rev fails to interact with these nucleoprotein components at the nucleus of 293 cells.  
  Several investigations have shown that Rev increases the translation of different 
mRNAs bearing the RRE [12,26,27]. Complexed with several cell proteins, these mRNAs can 
efficiently enter polysomes in the presence of Rev. Unless Rev is functional, the simple 
 
presence of these mRNAs in the cytoplasm is insufficient for their recognition by the 
translational apparatus. In the present set of experiments, we found that the translation of 
an HIV mRNA encoding Env which is transcribed in the nucleus of 293 cells is largely 
dependent on Rev. Thus, in these cells the translational apparatus does not recognise the 
env mRNA in the absence of Rev. Perhaps the binding of Rev to RRE acts as a signal 
identifying which mRNAs should be recognised by the translational machinery. Interaction 
of Rev with the components involved in the initiation of translation, including eIF5A, could 
be a prerequisite for these mRNAs to enter the polysomes. Alternatively, Rev may bind to 
other cell factors which inhibit mRNA translation to derepress the synthesis of Env.  
  Our findings certainly reveal that Rev enhances Env synthesis when its messenger is 
synthesised in the cytoplasm. In the vaccinia-VT7 system used here, there is no transport of 
mRNAs through the nuclear pores, yet Env synthesis is still enhanced by Rev. As to the role 
played by RRE, it seems clear that the simple presence of this motif on the luc mRNA does 
not confer Rev its stimulating capacity. However, the extent of stimulation is far below that 
found when a more physiological mRNA, such as the env mRNA, is used in the nuclear 
system. This means that besides RRE, there is a need for other elements or it is perhaps the 
global architecture of the HIV mRNA that is responsible for the regulatory role of Rev.   
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Figure legends  
 
Fig. 1. Effects of Rev on RRE env mRNA and Env protein in the 
cytoplasm of  
293 cells. 293 cells were transfected with 0.25 μg control pCDNA or pCDNA-env plasmids 
in the presence (+) or absence (-) of 0.5 μg pCDNA-rev. Forty-eight hours posttransfection, 
the cells were harvested and nuclear (N) and cytoplasmic (C) fractions separated. Panel A: 
Cytoplasmic fraction was analysed by Western blotting with Env polyclonal antiserum. Panel 
B: Luciferase activity was determined 48 h.p.t. in the cytoplasmic fraction of 293 cells. 
Transfections were performed using 0.25 μg pCDNA-RREluc with/without 0.5 μg pCDNA-rev. 
Panel C: Ethidium bromide staining after electrophoresis of agarose gel loaded with total 
RNA from cells transfected with pCDNA-env and pCDNA-rev. Panel D: RT-PCR amplification 
of cytoplasmic RNA using oligonucleotides detecting the cDNA of Env. Lane –RT corresponds 
control PCR without RT from cells transfected with pCDNA-env and lane C corresponds 
control RNA obtained by in vitro transcription from pKS-env plasmid. Panel E: Quantifying 
cytoplasmic env mRNA by real-time polymerase chain reaction.  
  
Fig. 2. Effect of Rev on Env synthesis using the recombinant vaccinia VT7 
system. HeLa and COS cell monolayers, treated with 40 μg /ml of ara-C, were infected with 
T7 recombinant vaccinia virus and subsequently transfected with 0.25 μg pKS or pKS-env in 
the presence (+) or absence (-) of 0.25 or 0.5 μg pTM1-rev plasmid. Sixteen hours 
posttransfection gp160 accumulated into cells was detected by western blotting using Env 
antiserum (Panel A). Similar infection/transfection experiment was performed using 
optimal concentration of pTM1 rev plasmid (0,5 μg). Fifteen hours posttransfection, the cells 
were pulse labelled with [35S]methionine for 1 hour and analysed by immunoprecipitation 
using Env polyclonal antiserum (Panel B). The bar chart (below) shows the quantification of 
the Env protein band Panel C: Western blotting using the Rev monoclonal antibody. Panel 
D: Two hours posttransfection, HeLa cells were treated (+) or not (- 
) with 10 mM neomycin B. Thirteen hours later, the cells were pulse labelled with [35S] 
methionine for 1 hour and immunoprecipitated with Env antiserum. The samples were 
analysed on polyacrylamide gels and visualised by autoradiography before (right) and after 
(left) immunoprecipitation.  
  
Fig. 3. Effect of Rev on luciferase synthesis from RRE-containing plasmids. 
Panel A: Schematic representation of the reporter plasmids. Panel B: Expression of the 
luciferase gene in a nuclear expression system. 293 cells were cotransfected with 0.5 μg 
control pCDNA (empty bars) or pCDNA-rev (black bars) and 0.1 μg (left graph) or 0.05 μg 
(right graph) pCDNA-luc or pCDNA-RREluc plasmids. Forty eight hours after transfection, 
luciferase activity was determined. Panel C: Expression of the luciferase gene in a 
cytoplasmic expression system. HeLa cells treated with 40 μg /ml ara-C were infected with 
T7 recombinant vaccinia virus and subsequently cotransfected with 0.5 μg control pTM1 
 
(empty bars) or pTM1-rev plasmids (black bars) and 0.1 μg (left graph) or 0.05 μg (right 
graph) pKS-luc or pKS-RREluc.  
Sixteen hours posttransfection, luciferase activity was determined.  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
  
  
  
 
 
